Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer

✍ Scribed by Silwan Chedid; Edgardo Rivera; Debbie K. Frye; Nuhad Ibrahim; Francisco Esteva; Vicente Valero; Gabriel Hortobagyi; Karl L. Mettinger; Massimo Cristofanilli

• Publisher: Springer
• Year: 2005
• Tongue: English
• Weight: 200 KB
• Volume: 57
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-005-0064-x